These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 29326074)

  • 1. Overcoming the resistance mechanisms of Smoothened inhibitors.
    Dong X; Wang C; Chen Z; Zhao W
    Drug Discov Today; 2018 Mar; 23(3):704-710. PubMed ID: 29326074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.
    Li QR; Zhao H; Zhang XS; Lang H; Yu K
    Acta Pharmacol Sin; 2019 Feb; 40(2):257-267. PubMed ID: 29777201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity.
    Zhang H; Sun Z; Liu Z; Song C
    Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small Molecule Inhibitors of the Hedgehog Pathway in the Treatment of Basal Cell Carcinoma of the Skin.
    Danhof R; Lewis K; Brown M
    Am J Clin Dermatol; 2018 Apr; 19(2):195-207. PubMed ID: 28887802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib.
    Danial C; Sarin KY; Oro AE; Chang AL
    Clin Cancer Res; 2016 Mar; 22(6):1325-9. PubMed ID: 26546616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABT-199 inhibits Hedgehog pathway by acting as a competitive inhibitor of oxysterol, rather as a BH3 mimetic.
    Wang J; Zhang Y; Huang WJ; Yang J; Tang WG; Huang TM; Tan WF
    Acta Pharmacol Sin; 2021 Jun; 42(6):1005-1013. PubMed ID: 32855528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures.
    Espinosa-Bustos C; Mella J; Soto-Delgado J; Salas CO
    Future Med Chem; 2019 Mar; 11(6):617-638. PubMed ID: 30912670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current trends in Hedgehog signaling pathway inhibition by small molecules.
    Ghirga F; Mori M; Infante P
    Bioorg Med Chem Lett; 2018 Oct; 28(19):3131-3140. PubMed ID: 30177379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo.
    Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S
    Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A sterol analog inhibits hedgehog pathway by blocking cholesterylation of smoothened.
    Liu YB; He LM; Sun M; Luo WJ; Lin ZC; Qiu ZP; Zhang YL; Hu A; Luo J; Qiu WW; Song BL
    Cell Chem Biol; 2024 Jul; 31(7):1264-1276.e7. PubMed ID: 38442710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the Oncoprotein Smoothened by Small Molecules: Focus on Novel Acylguanidine Derivatives as Potent Smoothened Inhibitors.
    Pietrobono S; Stecca B
    Cells; 2018 Dec; 7(12):. PubMed ID: 30558232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blocking smoothened cholesterylation: A strategy for overcoming drug resistance in cancer.
    Cheng SY; Zhang YE
    Cell Chem Biol; 2024 Jul; 31(7):1231-1233. PubMed ID: 39029450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.
    Kumari A; Ermilov AN; Grachtchouk M; Dlugosz AA; Allen BL; Bradley RM; Mistretta CM
    Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10369-E10378. PubMed ID: 29133390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies to target the Hedgehog signaling pathway for cancer therapy.
    Xin M; Ji X; De La Cruz LK; Thareja S; Wang B
    Med Res Rev; 2018 May; 38(3):870-913. PubMed ID: 29315702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Approaches in Non-Melanoma Skin Cancers-A Focus on Hedgehog Pathway in Basal Cell Carcinoma (BCC).
    Chmiel P; Kłosińska M; Forma A; Pelc Z; Gęca K; Skórzewska M
    Cells; 2022 Oct; 11(20):. PubMed ID: 36291078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hedgehog pathway and smoothened inhibitors in cancer therapies.
    Chahal KK; Parle M; Abagyan R
    Anticancer Drugs; 2018 Jun; 29(5):387-401. PubMed ID: 29537987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma.
    Chahal KK; Li J; Kufareva I; Parle M; Durden DL; Wechsler-Reya RJ; Chen CC; Abagyan R
    PLoS One; 2019; 14(9):e0214901. PubMed ID: 31539380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel indole derivative, 2-{3-[1-(benzylsulfonyl)piperidin-4-yl]-2-methyl-1H-indol-1-yl}-1-(pyrrolidin-1-yl)ethenone, suppresses hedgehog signaling and drug-resistant tumor growth.
    Jung JH; Lee H; Jeon J; Lee YJ; Nada H; Kim M; Lee H; Bhattarai D; Lee K; Ko HW
    Arch Pharm (Weinheim); 2024 Oct; 357(10):e2400218. PubMed ID: 38963677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A synthetic combinatorial approach to disabling deviant Hedgehog signaling.
    Fan CW; Yarravarapu N; Shi H; Kulak O; Kim J; Chen C; Lum L
    Sci Rep; 2018 Jan; 8(1):1133. PubMed ID: 29348431
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.